Meeting
2017 Gastrointestinal Cancers Symposium
Pancreatic neuroendocrine tumors: A population-based analysis of epidemiology and outcomes.
Authors
Samer Alsidawi
Mayo Clinic, Rochester, MN
Samer Alsidawi , Gustavo Figueiredo Marcondes Westin , Timothy J. Hobday , Thorvardur Ragnar Halfdanarson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 401)
DOI
10.1200/JCO.2017.35.4_suppl.401
Abstract #
401
Poster Bd #
J7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.
First Author: Heloisa P. Soares
Poster
2021 Gastrointestinal Cancers Symposium
Real-world efficacy and safety of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Estephany Abou Jokh Casas
Poster
2020 Gastrointestinal Cancers Symposium
Incidence and survival patterns of pancreatic neuroendocrine tumors over the last two decades: A SEER database analysis.
First Author: Mohamad Bassam Sonbol
Poster
2015 Gastrointestinal Cancers Symposium
A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET).
First Author: Aparna Kalyan